AxoGen (NASDAQ:AXGN – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Monday, Wall Street Zen reports.
A number of other equities analysts also recently commented on the stock. Morgan Stanley downgraded shares of AxoGen to a “hold” rating in a research note on Tuesday, September 29th. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Mizuho set a $65.00 price target on shares of AxoGen in a research note on Wednesday, October 28th. Bank of America assumed coverage on shares of AxoGen in a report on Monday, October 12th. They set a “buy” rating and a $52.00 price target for the company. Finally, Citizens Jmp lifted their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a research report on Thursday, July 30th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $57.92.
Check Out Our Latest Stock Analysis on AXGN
AxoGen Stock Down 0.0%
Shares of NASDAQ:AXGN opened at $55.37 on Monday. AxoGen has a 52-week low of $23.00 and a 52-week high of $59.72. The stock has a market cap of $3.31 billion, a P/E ratio of -85.18 and a beta of 1.21. The business has a fifty day moving average of $43.58 and a two-hundred day moving average of $40.65. The company has a quick ratio of 10.67, a current ratio of 12.02 and a debt-to-equity ratio of 0.04.
AxoGen (NASDAQ:AXGN – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.13 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.45 million. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. On average, research analysts expect that AxoGen will post -0.36 earnings per share for the current year.
Insider Activity
In related news, Director Joseph Tyndall sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the completion of the sale, the director directly owned 10,650 shares of the company’s stock, valued at approximately $529,305. This trade represents a 24.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.44% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. HighMark Wealth Management LLC lifted its position in shares of AxoGen by 0.3% during the third quarter. HighMark Wealth Management LLC now owns 342,490 shares of the medical equipment provider’s stock worth $14,357,000 after purchasing an additional 1,100 shares in the last quarter. Allworth Financial LP boosted its stake in shares of AxoGen by 78.5% in the third quarter. Allworth Financial LP now owns 848 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 373 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of AxoGen in the third quarter valued at approximately $1,823,000. Bamco Inc. NY boosted its stake in shares of AxoGen by 15.5% in the third quarter. Bamco Inc. NY now owns 854,945 shares of the medical equipment provider’s stock valued at $35,839,000 after purchasing an additional 114,735 shares during the period. Finally, Soleus Capital Management L.P. grew its holdings in shares of AxoGen by 1,795.3% in the third quarter. Soleus Capital Management L.P. now owns 1,081,000 shares of the medical equipment provider’s stock valued at $45,316,000 after purchasing an additional 1,023,964 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.
About AxoGen
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Recommended Stories
- Five stocks we like better than AxoGen
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
